|
|
|
|
|
1
|
Neuro Stents & Coils - Technology & Market Forecast |
May 2006 |
$780.00 |
|
The increase in use of non-invasive neuro-imaging modalities in the outpatient setting has led to a sharp increase in the number of truly asymptomatic, intracranial aneurysms being diagnosed.
Continuous improvement in coil design
more...
Published by: BioStrategy
|
|
|
2
|
Drug Eluting Stents - Technology & Market Forecast |
May 2006 |
$780.00 |
|
The introduction of Drug Eluting Stents has dramatically impacted the market size and growth rates for coronary stents worldwide. It has also impacted the distribution of market shares across the industry.
The Drug Eluting
more...
Published by: BioStrategy
|
|
|
3
|
Erythropoietin Current Market Dynamics & Future Outlook |
May 2005 |
$950.00 |
|
At the end of 2004 the world market for erythropoietin was valued at $11.1 billion, a growth of 8% over 2003. The market has been growing at an average annual growth rate of 18% over
more...
Published by: BioStrategy
|
|
|
4
|
Biopharmaceuticals - Current Market Dynamics & Future Outlook |
May 2005 |
$980.00 |
|
The biopharmaceutical market has come along way since 1982 when the first biopharmaceutical product, recombinant human insulin, was launched. Over 130 such products are currently being marketed around the world including thirteen blockbuster drugs.
more...
Published by: BioStrategy
| Search inside this report |
|
|
5
|
Monoclonal Antibody Therapeutics - Current Market Dynamics & Future Outlook |
May 2005 |
$780.00 |
|
The global market for Monoclonal Antibody (Mab) Therapeutics reached a total of $11.2 billion in 2004. The market has been growing at an impressive compound average annual growth rate of 42% over the previous five
more...
Published by: BioStrategy
| Search inside this report |
|
|
6
|
Colony Stimulating Factors - Current Market Dynamics & Future Outlook |
Dec 2004 |
$980.00 |
|
By the end of 2004 the world market for Colony Stimulating Factors was valued at $3.6 billion, a growth of 11% over 2003. The market has been growing at an average annual growth rate of
more...
Published by: BioStrategy
|
|
|
7
|
Erythropoietin - Current Market Dynamics & Future Outlook |
Oct 2004 |
$780.00 |
|
By the end of 2003 the world market for erythropoietin was valued at $10.3 billion, a growth of 14% over 2002. The market has been growing at an average annual growth rate of 21% over
more...
Published by: BioStrategy
| Search inside this report |
|
|
8
|
Monoclonal Antibody Therapeutics - Current Market Dynamics & Future Outlook |
Jun 2004 |
$780.00 |
|
The global market for Monoclonal Antibody (Mab) Therapeutics reached a total of $7.2 billion in 2003. The market has been growing at an impressive compound average annual growth rate of 53% over the previous five
more...
Published by: BioStrategy
| Search inside this report |
|
|
9
|
Biopharmaceuticals: Current Market Dynamics & Future Outlook |
Nov 2003 |
$780.00 |
|
This report reviews the current status of the market of biopharmaceuticals, highlights the differences between regional markets, maps leading biopharmaceutical classes and discusses the different windows of opportunities opening in this market including the potential
more...
Published by: BioStrategy
| Search inside this report |
|
|
10
|
Vascular Targeting Agents - State of the Science & Strategic Opportunities |
Jul 2003 |
$780.00 |
|
With the FDA granting “Fast Track” designation to OXiGENE’s lead Vascular Targeting Agent compound (CA4P) for the indication of Anaplastic Thyroid Cancer (ATC) and with OXiGENE filing for an “Orphan” drug status for this product,
more...
Published by: BioStrategy
| Search inside this report |
|
|
11
|
Aromatase Inhibitors, State of the Science & Strategic Opportunities |
May 2003 |
$480.00 |
|
In recent years, accumulating evidence has demonstrated the utility of aromatase inhibitors as therapy for postmenopausal women with estrogen receptor (ER) positive advanced breast cancer.
Aromatase inhibitors have already proved themselves superior, in
more...
Published by: BioStrategy
| Search inside this report |
|
|
12
|
Erythropoietin, State of the Science & Strategic Opportunities |
Nov 2002 |
$480.00 |
|
By the end of 2001 the world market for recombinant human erythropoietin (rHuEpo) was valued at $5.3 billion, a growth of 12% over 2000. The market has been growing at an 11% average annual growth
more...
Published by: BioStrategy
| Search inside this report |
|
|
13
|
Human Growth Hormone |
Mar 2001 |
$480.00 |
|
The approval, by the FDA, of Pharmacia's Genotropin for the long-term treatment of growth failure in children with Prader-Willi syndrome (PWS) has revitalized the market for Human Growth Hormone which is expected to reach US$2.2
more...
Published by: BioStrategy
| Search inside this report |
|
|
14
|
Angiogenesis Inhibitors in Cancer Research |
Mar 2001 |
$480.00 |
|
Anti-angiogenic agents are believed to hold great promise in the fight against cancer. With more than 70 of such agents in different stages of clinical development, angiogenesis inhibitors are considered one of the most exciting
more...
Published by: BioStrategy
| Search inside this report |
|
|
|
|
|
0 items
